Compare ARK Genomic Revolution ETF (ARKG) vs CarMax, Inc (KMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ARK Genomic Revolution ETF vs CarMax, Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.9, while CarMax, Inc trades at $55.1 (market cap $7.59B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | KMX | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $65.20 |
52-Week Low | $23.09 | $30.88 |
Market Cap | — | $7.59B |
Enterprise Value | — | $26.10B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
CarMax (KMX) trades at $53.49, up 4.86% with a bullish technical signal. The stock shows mixed fundamentals with a P/E of 33.22 and net margin of 0.84%, though recent Q1 2026 earnings beat expectations. Revenue trends downward from $31.9B in 2022 to $26.4B in 2025, while net cash flow turned negative at -$290M. Analyst sentiment is cautious with 62.9% hold ratings and a $48.91 consensus target below current price. Recent news highlights a four-pillar turnaround strategy under new CEO Keith Barr.
KMX presents a speculative opportunity amid transition, with potential upside from execution of digital and cost initiatives. Key risks include margin pressure, high debt load ($18.1B long-term), and investigation concerns. Near-term resistance at $53, support at $49. Wall Street remains neutral pending clearer turnaround evidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →
